Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Molecular Cancer Therapeutics

• Publication date

  2007-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1535-7163.MCT-07-0297PMID 17989319PMCID PMC2613795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers

  2021cited by this paper
• Thrombospondin-1 limits ischemic tissue survival by inhibiting nitric oxide-mediated vascular smooth muscle relaxation.

  2007cited by this paper
• A Mouse Model with Liver-Specific Deletion and Global Suppression of the NADPH-Cytochrome P450 Reductase Gene: Characterization and Utility for in Vivo Studies of Cyclophosphamide Disposition

  2007cited by this paper
• Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model

  2007cited by this paper
• Targeting of the receptor protein tyrosine phosphatase beta with a monoclonal antibody delays tumor growth in a glioblastoma model.

  2006cited by this paper
• Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors

  2006cited by this paper
• A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype.

  2006cited by this paper
• Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11

  2006cited by this paper
• Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy.

  2006cited by this paper
• Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models.

  2006cited by this paper
• Peritoneal cancer treatment with CYP2B1 transfected, microencapsulated cells and ifosfamide

  2006cited by this paper
• Aptamer:toxin conjugates that specifically target prostate tumor cells.

  2006cited by this paper
• Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

  2006cited by this paper
• Lessons from phase III clinical trials on anti-VEGF therapy for cancer

  2006cited by this paper
• Thrombospondin-1 is Induced in Rat Myocardial Infarction and Its Induction is Accelerated by Ischemia/Reperfusion

  2005cited by this paper
• Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.

  2005cited by this paper
• Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner.

  2005cited by this paper
• Brain tumor oncolysis with replication-conditional herpes simplex virus type 1 expressing the prodrug-activating genes, CYP2B1 and secreted human intestinal carboxylesterase, in combination with cyclophosphamide and irinotecan.

  2005cited by this paper
• A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

  2005cited by this paper
• Phase I Study of MetXia-P450 Gene Therapy and Oral Cyclophosphamide for Patients with Advanced Breast Cancer or Melanoma

  2005cited by this paper
• Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation.

  2005cited by this paper
• Immunohistochemical expression of thrombospondin-1 in invasive vulvar squamous cell carcinoma.

  2005cited by this paper
• Function of endogenous inhibitors of angiogenesis as endothelium-specific tumor suppressors.

  2005cited by this paper
• Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1

  2005cited by this paper
• Cell death by mitotic catastrophe: a molecular definition

  2004cited by this paper
• Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression

  2004cited by this paper
• Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.

  2004cited by this paper
• Use of Replication-Conditional Adenovirus as a Helper System to Enhance Delivery of P450 Prodrug-Activation Genes for Cancer Therapy

  2004cited by this paper
• Harnessing apoptosis for improved anticancer gene therapy.

  2003cited by this paper
• Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35.

  2002cited by this paper
• Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water.

  2002cited by this paper
• Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium–derived factor

  2002cited by this paper
• Treatment of inoperable pancreatic carcinoma using a cell-based local chemotherapy: results of a phase I/II clinical trial.

  2002cited by this paper
• Cyclophosphamide induces caspase 9-dependent apoptosis in 9L tumor cells.

  2001cited by this paper
• Modulation of cyclophosphamide-based cytochrome P 450 gene therapy using liver P450 inhibitors

  2001cited by this paper
• Thrombospondin-1-mediated metastasis suppression by the primary tumor in human melanoma xenografts.

  2001cited by this paper
• Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy.

  2001cited by this paper
• POLYPLOID GIANT CELLS PROVIDE A SURVIVAL MECHANISM FOR p53 MUTANT CELLS AFTER DNA DAMAGE

  2000cited by this paper
• Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer.

  2000influential reference
• Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model

  2000cited by this paper
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

  2000cited by this paper
• Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

  2000cited by this paper
• A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

  1998cited by this paper
• Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy.

  1998cited by this paper
• Rapid growth of cutaneous metastases after surgical resection of thrombospondin-secreting small blue round cell tumor of childhood.

  1998cited by this paper
• Protein-bound acrolein: potential markers for oxidative stress.

  1998cited by this paper
• Metabolism and binding of cyclophosphamide and its metabolite acrolein to rat hepatic microsomal cytochrome P-450.

  1984cited by this paper
• Tumor angiogenesis: therapeutic implications.

  1971cited by this paper

• Drug delivery strategies in maximizing anti-angiogenesis and anti-tumor immunity.

  2021cites this paper
• Aspects of Chemotherapy in Prostate Cancer

  2021cites this paper
• Targeted Therapies in Veterinary Oncology.

  2019cites this paper
• The Anticancer Drug Ellipticine Activated with Cytochrome 3 P450 Mediates DNA Damage that Determines its 4 Pharmacological Efficiencies: Studies with Knockout Mouse 5 Models and Pure Enzymes

  2015cites this paper
• The Anticancer Drug Ellipticine Activated with Cytochrome

  2015cites this paper
• The Anticancer Drug Ellipticine Activated with Cytochrome P450 Mediates DNA Damage Determining Its Pharmacological Efficiencies: Studies with Rats, Hepatic Cytochrome P450 Reductase Null (HRN™) Mice and Pure Enzymes

  2014cites this paper
• Adenoviral vectors for prodrug activation-based gene therapy for cancer.

  2014cites this paper
• Important Role of CYP2J2 in Protein Kinase Inhibitor Degradation: A Possible Role in Intratumor Drug Disposition and Resistance

  2014cites this paper
• Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2

  2014cites this paper
• The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice.

  2013cites this paper
• Impact of Tumor Vascularity on Responsiveness to Antiangiogenesis in a Prostate Cancer Stem Cell-Derived Tumor Model

  2013cites this paper
• Impact of Tumor Blood Flow Modulation on Tumor Sensitivity to the Bioreductive Drug Banoxantrone

  2013cites this paper
• Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis.

  2013cites this paper
• Development of bacterial nitroreductase enzymes for noninvasive imaging in cancer gene therapy

  2013cites this paper
• Ellipticine oxidation and DNA adduct formation in human hepatocytes is catalyzed by human cytochromes P450 and enhanced by cytochrome b5.

  2012cites this paper
• Tumor pO₂ as a surrogate marker to identify therapeutic window during metronomic chemotherapy of 9L gliomas.

  2011cites this paper
• Cytochrome P450- and peroxidase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efficiency.

  2011cites this paper
• Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer.

  2010cites this paper
• Engineering cytochrome P450 biocatalysts for biotechnology, medicine and bioremediation

  2010influential citation
• The Biomodulatory Capacities of Low-Dose Metronomic Chemotherapy: Complex Modulation of the Tumor Microenvironment

  2010cites this paper
• Dominant Effect of Antiangiogenesis in Combination Therapy Involving Cyclophosphamide and Axitinib

  2009cites this paper
• Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agents.

  2009cites this paper
• Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib

  2008cites this paper
• Combination of antiangiogenesis with chemotherapy for more effective cancer treatment

  2008cites this paper
• Prodrug cancer gene therapy.

  2008cites this paper
• Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11

  2006cites this paper